Amgen, Inc. (NASDAQ:AMGN) Position Lessened by Quilter Investors LTD

Share on StockTwits

Quilter Investors LTD reduced its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 52.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,494 shares of the medical research company’s stock after selling 10,548 shares during the period. Amgen accounts for approximately 1.7% of Quilter Investors LTD’s portfolio, making the stock its 21st biggest holding. Quilter Investors LTD’s holdings in Amgen were worth $1,749,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Qube Research & Technologies Ltd increased its stake in shares of Amgen by 1.5% in the second quarter. Qube Research & Technologies Ltd now owns 15,052 shares of the medical research company’s stock worth $2,774,000 after purchasing an additional 225 shares during the period. Hillsdale Investment Management Inc. grew its position in Amgen by 9.2% during the second quarter. Hillsdale Investment Management Inc. now owns 3,310 shares of the medical research company’s stock worth $609,000 after buying an additional 280 shares in the last quarter. GHP Investment Advisors Inc. grew its position in Amgen by 3.8% during the second quarter. GHP Investment Advisors Inc. now owns 10,509 shares of the medical research company’s stock worth $1,937,000 after buying an additional 385 shares in the last quarter. Whitener Capital Management Inc. grew its position in Amgen by 41.0% during the second quarter. Whitener Capital Management Inc. now owns 8,982 shares of the medical research company’s stock worth $1,655,000 after buying an additional 2,610 shares in the last quarter. Finally, John G Ullman & Associates Inc. grew its position in Amgen by 1.5% during the second quarter. John G Ullman & Associates Inc. now owns 11,622 shares of the medical research company’s stock worth $2,142,000 after buying an additional 172 shares in the last quarter. Institutional investors own 78.96% of the company’s stock.

A number of equities research analysts recently weighed in on the company. Piper Jaffray Companies set a $210.00 target price on Amgen and gave the stock a “buy” rating in a research report on Saturday, August 10th. Oppenheimer increased their price objective on shares of Amgen from $210.00 to $230.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 13th. Evercore ISI restated a “hold” rating on shares of Amgen in a research note on Sunday, August 11th. Wells Fargo & Co increased their price objective on shares of Amgen from $197.00 to $202.00 and gave the stock a “market perform” rating in a research note on Monday, August 12th. Finally, Mizuho restated a “buy” rating and set a $208.00 price objective on shares of Amgen in a research note on Monday, July 1st. Nine equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $212.72.

Shares of AMGN stock traded up $4.71 on Friday, reaching $204.02. The stock had a trading volume of 2,922,500 shares, compared to its average volume of 3,881,659. The company has a quick ratio of 2.60, a current ratio of 2.89 and a debt-to-equity ratio of 2.58. The firm’s 50-day moving average is $183.92 and its two-hundred day moving average is $182.82. The firm has a market capitalization of $119.53 billion, a price-to-earnings ratio of 14.17, a P/E/G ratio of 2.34 and a beta of 1.19. Amgen, Inc. has a 12 month low of $166.30 and a 12 month high of $211.90.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, July 30th. The medical research company reported $3.97 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.58 by $0.39. The firm had revenue of $5.87 billion for the quarter, compared to analysts’ expectations of $5.67 billion. Amgen had a net margin of 33.78% and a return on equity of 76.17%. The business’s revenue was down 3.1% on a year-over-year basis. During the same period in the prior year, the firm earned $3.83 EPS. On average, sell-side analysts forecast that Amgen, Inc. will post 14.25 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 6th. Shareholders of record on Thursday, August 15th will be issued a $1.45 dividend. The ex-dividend date of this dividend is Wednesday, August 14th. This represents a $5.80 annualized dividend and a yield of 2.84%. Amgen’s dividend payout ratio is currently 40.28%.

In other Amgen news, Director Ronald D. Sugar sold 2,000 shares of the stock in a transaction dated Wednesday, July 3rd. The shares were sold at an average price of $187.58, for a total value of $375,160.00. Following the transaction, the director now directly owns 16,336 shares of the company’s stock, valued at approximately $3,064,306.88. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director R Sanders Williams sold 425 shares of the stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $183.04, for a total transaction of $77,792.00. Following the completion of the transaction, the director now directly owns 16,336 shares in the company, valued at $2,990,141.44. The disclosure for this sale can be found here. Over the last three months, insiders sold 4,425 shares of company stock worth $804,312. Insiders own 0.25% of the company’s stock.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Recommended Story: How does a reverse stock split work?

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.